Menu
Not yet recruiting NCT07581886

sACB vs cACB in TKA

No phase Interventional Arthroplasty Replacement Knee

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Continuous ACB, Single-shot ACB.
Who it may be relevant to
Registry conditions: Arthroplasty, Replacement, Knee. Basic parameters: 40 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Comparison of Single-shot vs. Continuous Adductor Canal Block Analgesic Effects With Catheter Positioning Confirmation in Total Knee Arthroplasty: a Double-blinded Prospective Randomized Controlled Trial

Overview

This study compares the analgesic efficacy of single-dose adductor canal block (sACB) versus continuous-dose adductor canal block (cACB) for postoperative pain management in total knee replacement patients. To ensure a high level of clinical accuracy, the investigation specifically focuses on a cACB cohort where ultrasound confirmation ensures the catheter remains correctly positioned for a full 48 hours. Participants are assigned to groups using a 1:1 randomization protocol via computer-generated tables to eliminate selection bias. Clinical consistency is maintained by using identical pharmacological agents across both groups: 0.5% Heavy Bupivacaine for spinal anesthesia and 0.5% ropivacaine with 1:200,000 epinephrine for the nerve block itself. Furthermore, both groups adhere to a standardized multimodal analgesic schedule to control for external variables. In the cACB group, intravenous patient-controlled analgesia (IV PCA) serves as a designated rescue therapy should the catheter fail. The primary technical evaluation occurs 48 hours post-surgery, utilizing ultrasound to verify catheter placement and quantify pain levels. Beyond immediate recovery, the study evaluates long-term success through Patient-Reported Outcome Measures (PROMs) at a 12-week follow-up, focusing on functional restoration and the patient's overall quality of life. By isolating the variable of catheter stability, the research aims to provide a definitive comparison of whether the continuous delivery of local anesthetic offers a statistically significant clinical advantage over a single-dose administration in the context of modern orthopedic recovery protocols.

Interventions

  • Procedure Continuous ACB
    Adductor canal block, a lower extremity nerve block technique for postoperative pain control, is performed under ultrasound guidance for patients undergoing total knee arthroplasty, and is carried out by inserting a catheter. The catheter is connected to a PCA pump following insertion, with a continuous infusion rate for two days post-surgery.
  • Procedure Single-shot ACB
    Adductor canal block, a lower extremity nerve block technique for postoperative pain control, is performed under ultrasound guidance for patients undergoing total knee arthroplasty, and is carried out by a single-shot local anesthetic administration.

Primary outcome measures

  • postoperative pain score at rest (Area Under Curve, AUC) [Time frame: postoperative 48 hours]

Eligibility criteria

Inclusion criteria

  • Age 40-80 yrs
  • Scheduled for unilateral total knee arthroplatsy
  • ASA I-III
  • BMI 18-35 kg/㎡
  • Able to read and understand consent form

Exclusion criteria

  • Allergy to local anesthetics
  • Infection at the block site
  • History of neuropathy or peripheral nerve disease
  • Coagulation disorders or use of anticoagulants (if discontinuation is not possible)
  • Communication disorders or cognitive impairment
  • Chronic opioid use (≥30 MME/day, 3 months or more)
  • Severe chronic pain (NRS ≥7/10, 3 months or more)
  • Renal impairment (eGFR <30 mL/min/1.73m²)
  • Hepatic impairment (Child-Pugh C)
  • Blood coagulation disorders
  • Pregnancy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07581886 · 4-2026-0299

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗